ABBV vs MRK
By Alex · Tickerpine
AbbVie Inc. vs Merck & Co., Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | MRK |
|---|---|---|
| Price | $265.79 | $156.45 |
| Market cap | $469.68B | $385.99B |
| P/E ratio | 74.7 | 120.3 |
| ROE | — | 6.96% |
| Profit margin | 9.80% | 4.77% |
| Revenue growth | 10.20% | 5.10% |
| Dividend yield | 2.62% | 2.26% |
| Beta | 0.28 | 0.21 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs MRK in plain English
- ABBV is the bigger company — about 1.2× the market cap of MRK.
- ABBV is cheaper on earnings (P/E 74.7 vs 120.3).
- ABBV is growing revenue faster (10% vs 5%).
- ABBV has the higher dividend yield (2.62% vs 2.26%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.